DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

M K Proteins Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·14 Oct 2026, 7:15 am

M K Proteins

M K Proteins Limited has informed the stock exchanges about the issuance of a certificate under SEBI's Depositories and Participants Regulations, 2018. This regulatory filing is a standard procedural update that confirms the company's compliance with the rules governing its securities and depository operations. It is a routine administrative step rather than a major corporate development.

For investors, this news is neutral and does not signal any immediate change in the company's operational or financial outlook. It serves as a confirmation that the company is adhering to the regulatory framework set by the Securities and Exchange Board of India (SEBI). The stock is expected to trade with no significant impact based on this specific announcement.

Investors should monitor the company's future quarterly results and operational performance to gauge its true growth trajectory. This regulatory update is not a trigger for any immediate trading action, but it does maintain the company's compliance status with market watchdogs.